Systemic Injection of Substance P Promotes Murine Calvarial Repair Through Mobilizing Endogenous Mesenchymal Stem Cells

Yueling Zhang, Shu An, Jin Hao, Feng Tian, Xinyi Fang & Jun Wang

Craniofacial defect is a critical problem in dental clinic, which has a tremendous impact on patients’ quality of life. Mesenchymal stem cell-based therapy has emerged as a promising approach for tissue defect repair. However, reduced survival after mesenchymal stem cells (MSCs) transplantation remains as a major problem in this area, which hampers the outcome of regeneration. Recently, the mechanism to mobilize endogenous MSCs for tissue regeneration has received increasing attentions, as it does not require exogenous cell transplantation. The primary goal of this study was to confirm the role of intravenous substance P in mobilizing endogenous CD45−CD11b−CD29+ MSCs in critical-sized bone defect animals and to investigate the effects of substance P on calvarial bone repair. Flow cytometry analyses revealed that intravenous substance P promoted the mobilization of endogenous CD45−CD11b−CD29+ MSCs after bone defect. In addition, Micro-CT showed that intravenous substance P improved the outcomes of calvarial bone repair. Furthermore, we discovered that systemic injection of substance P attenuated inflammation and enhanced the survival of the local-transplanted GFP+MSCs. Our findings suggested that substance P together with its mobilized CD45−CD11b−CD29+ MSCs helped improve calvarial defect repair through regulating inflammatory conditions and promoting the survival of local-transplanted cells.

The cranium is a highly complex region of human body and deputes to many fundamental functions including eating, speech, expression of emotions, and the delivery of sensations. Therefore, craniofacial defects, as one of the most common problems in oral clinics, can lead to a tremendous impact on patients’ quality of life. The current treatment for craniofacial defects includes autologous tissue grafts, allogeneic tissue grafts, and xenogeneic tissue grafts. However, such procedures bear the risks of donor-site morbidity, poor biocompatibility, and immune rejection. Given the limitations of these tissue graft-based approaches, stem cell-based therapies have emerged as a promising approach for tissue defect repair.

Despite recent progress in stem cell transplantation, such method still has several problems, including increased cell death and risk of side effects, such as hypersensitivity to stimuli after transplantation. In addition, a recent study shows that the endogenous pro-inflammatory T cells may impede stem cell transplantation-based bone repair through IFN-γ and TNF-α pathways.

Recently, researchers have found that endogenous MSCs can provide a novel source for defect repair and may overcome the above limitations. These endogenous MSCs are present in multiple adult tissues and can be recruited to the injury site after stimulation. In addition to their multipotency, they have excellent capability of immunomodulation in controlling inflammation after injury, contributing to tissue repair.

The next critical step would be to promote the mobilization of these endogenous MSCs to the injured tissue. Recently, researchers have demonstrated that substance P, as an injury-inducible messenger, can act early in the wound healing process and mobilize CD45−CD11b−CD29+ MSCs from bone marrow into peripheral circulation using corneal injury model.

1 State Key Laboratory of Oral Diseases, Department of Orthodontics, West China School of Stomatology, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, 610041, China. 2Harvard School of Dental Medicine, Harvard University, Boston, MA, 02115, USA. 3F.M. Kirby Neurobiology Center, Boston Children’s Hospital and Harvard Medical School, Boston, MA, 02115, USA. Yueling Zhang and Shu An contributed equally. Correspondence and requests for materials should be addressed to J.W. (email: wangjunv@scu.edu.cn)
In this study, we identified whether systemic delivery of substance P can promote endogenous MSCs mobilization and homing in mice with calvarial defects. Next, we evaluated the inflammation state through analyses of pro-inflammatory cytokine expression in both injury sites and peripheral circulation. Finally, we tested the capacity of systemic-injected substance P in promoting calvarial defect repair. Here, we demonstrated that systemic delivery of substance P could promote CD45−CD11b−CD29+ MSCs mobilization and calvarial defect repair.

In addition, our study indicated the potential role of systemic-injected substance P in regulating inflammation during bone healing process.

**Results**

**Substance P mobilized CD45−CD11b−CD29+ cells.** Previous studies had reported that substance P had a strong mobilization effect on the endogenous CD45−CD11b+CD29+ cell population at early stage in corneal burn injury models. These cells all expressed similar molecular markers with BMSCs and had multipotent differentiation capacities at early passages.

To identify the function of systemically injected substance P in the bone defect model, we established the calvarial critical-sized defect model with a diameter of 5 mm and gave each mouse a systemic injection of substance P (5 nmol/kg) through the tail vein. 3 days after surgery, we collected 1 ml peripheral blood and counted CD45−CD11b−CD29+ cells using flow cytometry. The absolute numbers of CD45−CD11b−CD29+ cells in peripheral blood from the other three groups (injured or i.v. substance P) were significantly higher than that of the uninjured group (Fig. 1a,b) (P < 0.01). This indicated that both calvarial injury and i.v. substance P could promote the enrichment of CD45−CD11b−CD29+ cells in peripheral blood. Meanwhile, no significant differences were observed between uninjured + i.v. substance P group and calvarial injured + i.v. substance P group (P > 0.05) (Fig. 1b). Both groups exhibited a larger number of cells than the calvarial injured group (P < 0.01) (Fig. 1b), indicating that the motivation capability of i.v. substance P was much greater than injury itself.

To confirm that i.v. substance P helps motivate the CD45−CD11b−CD29+ cell population specifically, we measured the relative number of this cell population together with the total cell number in collected peripheral blood (Fig. 1c,d). The percentage of CD45−CD11b−CD29+ cells in peripheral blood of the calvarial injured group (0.5% ± 0.1) was significantly higher than that of the uninjured group (0.267% ± 0.12) (P < 0.05) (Fig. 1c). There was no significant difference between the uninjured + i.v. substance P group and calvarial injured + i.v. substance P group (0.867% ± 0.05) and the calvarial injured + i.v. substance P group (0.967% ± 0.12) (P > 0.05), and both groups had a larger number than that in the calvarial injured and uninjured groups (P < 0.01) (Fig. 1c). In addition, there was no significant difference in the total cell number of peripheral blood among the four groups (P > 0.05) (Fig. 1d).

We also tested the in vitro role of substance P in proliferation of CD45−CD11b−CD29+ cell population using cell counting and CCK-8 (Fig. 2a–c). The statistic analyses have shown that substance P stimulation could increase the proliferation of these mobilized CD45−CD11b−CD29+ cells.

**Intravenous substance P controls inflammatory state both systemically and locally in calvarial injured mice.** Substance P plays an important role in neurogenic inflammation and can promote the infiltration of inflammatory cells. Also, substance P can stimulate the secretion of TNF-α from mononuclear-macrophage. To evaluate the inflammatory state of the calvarial injured animal after systemic injection of substance P, we carried out ELISA of the peripheral blood, western blot, and RT-PCR of the tissue within the primary defect areas 2 weeks after the surgery.

First of all, ELISA analyses of peripheral blood have revealed that the inflammation was attenuated with decreased concentration of pro-inflammatory cytokine IFN-γ and TNF-α in peripheral circulation after systemic injection of MSCs or substance P (Fig. 3a,b) (P < 0.05). It has also been reported that TSG-6 can be secreted by intravenous MSCs, which is able to abort the early inflammatory response through the modulation of nuclear factor NF-kB signaling in resident macrophages. In the current study, ELISA analyses have demonstrated that the TSG-6 expression levels in peripheral circulation were significantly higher in groups using intravenous MSCs or substance P than that of the other groups (Fig. 3c) (P < 0.01).

Secondly, western blot analyses of tissue within the primary defect areas have shown that the expression of IFN-γ and TNF-α was significantly reduced after systemic application of MSCs or substance P (Fig. 3d,e) (P < 0.05). RT-PCR analyses of primary injured tissues further confirmed that the corresponding mRNA expression of IFN-γ and TNF-α were also inhibited in i.v.GFP+ MSC and GFP+ MSC + i.v. substance P groups (Fig. 3f) (P < 0.05). Additionally, both the mRNA and corresponding protein expression of TSG-6 at the local injury site were enhanced after intravenous MSCs or substance P injection, as shown by RT-PCR and western blot, respectively (Fig. 3e,f) (P < 0.01). Interestingly, the TSG-6 expression level in i.v.GFP+ MSC group was similar to that in GFP+ MSC + i.v. substance P group (Fig. 3e) (P > 0.05), suggesting that substance P-mobilized CD29+ cells, like intravenous exogenous MSCs, could also secrete TSG-6 to help control inflammation.

Recent research has also demonstrated that IFN-γ can inhibit the osteogenesis of exogenous bone marrow MSCs through downregulation of Runx2 pathway. To address this critical question, we evaluated the mRNA and protein expression of Runx2 within the primary injury site. The results showed that Runx2 expression increased in GFP+ MSC + i.v. substance P group compared with those in other groups (Fig. 3e,f) (P < 0.01). This indicated that the survival and osteogenic capacity of MSCs within the defect in GFP+ MSC + i.v. substance P group was higher than those in other groups, which was potentially due to substance P-mediated inflammatory states.

To further confirm the effect of substance P-mediated inflammation on survival of transplanted GFP+ MSCs, we checked the GFP signal using real-time in vivo GFP fluorescence imaging (Fig. 4a–d). The GFP signal was significantly higher in GFP+ MSC + i.v. substance P group than in GFP+ MSCs-scaffold group (Fig. 4a–d) (P < 0.05), indicating the enrichment of CD45−CD11b−CD29+ cells.
suggesting that i.v. substance P might enhance the survival of GFP+ MSCs within the defect areas. We also compared the mRNA and protein expression of GFP in defect areas among groups (Fig. 4e–g). The expression of GFP was only detected within groups using GFP+ MSCs-seeded scaffold, confirming that intravenous exogenous GFP+ MSCs could hardly reach the injury site. The statistical analyses indicated that the GFP expression was significantly higher in GFP+ MSCs-seeded scaffold group than in GFP+ MSCs-scaffold group (Fig. 4f,g) (P < 0.05), which was consistent with real-time in vivo GFP fluorescence imaging data.

All the above results suggested that intravenous substance P could control the inflammatory state both locally and systemically in the calvarial critical-sized defect model.

Figure 1. Substance P mobilized CD45−CD11b−CD29+ cells after calvarial defect. C57BL/6 wide-type mice were divided into four groups: uninjured group (no injury), calvarial injured group, uninjured + i.v. substance P, calvarial injured + i.v. substance P. (a) 3 days after setting up the animal model, 1 ml peripheral blood was collected from each group for flow cytometry. (b) The absolute number of CD45−CD11b−CD29+ cells per 1 ml peripheral blood. (c) The relative number of CD45−CD11b−CD29+ cells per 1 ml peripheral blood. (d) The total cell numbers per 1 ml peripheral blood. For a, b, c and d, n = 3 for all groups. Analysis of variance *P < 0.05, **P < 0.01. NS indicates not significant.
Intravenous substance P promoted calvarial injury repair. Considering that substance P can mobilize CD29+ cells, which demonstrate multipotent differentiation capacity and can control the inflammatory state after injury, we wonder whether intravenous substance P can promote bone repair in calvarial defects. The hematoxylin-eosin staining showed that there were more bone-like structures formed within the primary defect areas in GFP+MSC+i.v. substance P group compared with other groups (Fig. 5). Consistently, the reconstructed three-dimensional images of Micro CT showed that the remaining defect area after repair was much smaller in GFP+MSC+i.v. substance P group than that of the other groups (Fig. 6a), which suggested that more new bones were formed in GFP+MSC+i.v. substance P group. Further analyses of the bone parameters from Micro CT images suggested that both systemic injection of MSCs and substance P enhanced calvarial bone repair while intravenous substance P brought about better effects than intravenous MSCs in calvarial defect mice (Fig. 6b–g) \( P < 0.05 \).

Discussion
Recently, researchers have revealed that substance P, as a damage-inducible factor, is a powerful factor for mobilizing endogenous MSCs in corneal burn injury\(^{12}\). In our study, we confirmed the ability of substance P in endogenous MSCs mobilization at the early stage of bone injury. These results suggest that substance P may provide a promising candidate for mobilizing endogenous MSCs in different kinds of injury models. Based on previous literature, these substance P-mobilized MSCs may be derived from the bone marrow\(^ {12}\). Unfortunately, with current techniques, we cannot demonstrate their definite origin. However, we provided some evidence regarding the potential origin of these mobilized cells. On one hand, the molecular markers of substance P mobilized cells are similar to those of BMSCs derived from the bone marrow\(^ {12}\). On the other hand, the *in vitro* experiment showed

---

**Figure 2.** Substance P stimulated the proliferation of CD45−CD11b−CD29+ cells. (a) Representative pictures of cell counting assay for control group and SP group (1 × 10^{-6} mol/l) at 0, 24 and 48 hours respectively. (b) Statistical analysis of viable cell numbers within four groups after 48-hour treatment. (c) CCK-8 analysis of four groups after 48-hour treatment (0 mol/l, 1 × 10^{-10} mol/l, 1 × 10^{-8} mol/l and 1 × 10^{-6} mol/l). * means \( P < 0.05 \). ** means \( P < 0.01 \).
that substance P could stimulate the proliferation of those mobilized cells, which was consistent with the effect of substance P on BMSCs. Taking all these together, we speculate that these mobilized cells may be derived from the bone marrow, which may contribute to clavicular bone repairing.
Inflammatory state has been evidenced to be critical for tissue regeneration. Previous studies have focused on the pro-inflammatory roles of substance P as a damage-inducible factor. It has also been reported that substance P can promote the infiltration of inflammatory cells and stimulate secretion of TNF-α from mononuclear-macrophage. In the mouse liver injury model, the inflammation of mice liver was attenuated after administration of NK-1R (a receptor of substance P) antagonists and levels of TNF-α and IFN-γ in serum.

**Figure 4.** Real-time in vivo GFP fluorescence imaging. C57BL/6 wide-type mice were divided into five groups: control group, blank scaffold group, i.v.GFP+MSCs group, GFP+MSCs-scaffold group, GFP+MSCs + i.v.substance P group. (a) 12 weeks post surgery, the expression of GFP+ signal was detected by Bio-Real in vivo imaging system. (b) The total fluorescence area for the latter three groups. (c) The total fluorescence for the latter three groups. (d) Mean fluorescence intensity for the latter three groups. (e) Representative images of western blot for GFP within defect areas in the latter four groups. (f) Western blot analysis for relative GFP expression within defect areas. (g) RT-PCR analysis for relative GFP mRNA expression within defect areas. n = 3 for all groups. Analysis of variance *P < 0.05, **P < 0.01.
were also reduced\textsuperscript{17}. To identify the effects of intravenous substance P on inflammatory status of our calvarial defect animals, we assessed the pro-inflammatory protein levels both locally and systemically. Interestingly, in the current study, the inflammation was significantly attenuated by systemic infusion of substance P. Previous studies have shown that exogenous substance P has a short half-life while endogenous injured tissue-derived substance P has mostly regressed by Day 3 after injury\textsuperscript{12,18}. In this way, the alleviated inflammatory state at 2 weeks

**Figure 5.** HE staining of calvarial defect areas. C57BL/6 wide-type mice were divided into five groups: control group, blank scaffold group, i.v.GFP\textsuperscript{+} MSCs group, GFP\textsuperscript{+} MSCs-scaffold group, GFP\textsuperscript{+} MSCs + i.v.substance P group. H&E staining of calvarial defect areas for each group. Red arrow indicates the scaffold. Black arrows indicate new bone formation at the margin of calvarial defects. Blue arrow indicates new bone island formation within primary injury site.
Figure 6. Micro-CT image reconstruction of calvarial defect areas. C57BL/6 wide-type mice were divided into five groups: control group, blank scaffold group, i.v.GFP+MSCs group, GFP+MSCs-scaffold group, GFP+MSCs+i.v.substance P group. (a) Micro-CT images and reconstruction of the critical-sized calvarial defects at the 12th week. The blue circular regions on the 2nd line present the configuration of surgery-created defects with a diameter of 5 mm. The blue structures within the circles stand for the new-formed bone-like tissue. The 3rd line is a magnification of the defect area. (b) The total volume of new-formed bone. (c) The bone mineral density (BMD) of new-formed bone. (d) The bone volume fraction (BV/TV): the percentage of the new formed bone in the total calvarial bone volume. (e) Mean trabecular bone thickness of new-formed bone. (f) The average number of trabecular bones. (g) Mean trabecular space within the repair areas. n = 3 for all groups. Analysis of variance *P < 0.05, **P < 0.01. NS indicates not significant.
after surgery, we collected 1 ml peripheral blood and counted CD45 systemically. Injection of substance P (5 nmol/kg, dissolved in phosphate-buffered saline) through the tail vein. 3 days fold group, we put the 5
1
in
local-transplanted MSCs survival through its mobilized endogenous MSCs. However, more experiment, like in vitro cell experiment, is needed to fully elucidate the underlying mechanisms.

In addition, the bone parameters from Micro CT analysis revealed that the new bone formation was enhanced after systemic application of MSCs or substance P. Interestingly, the outcome in GFP + MSCs + i.v. substance P group was even better than that in i.v. GFP + MSC group, which might be explained by pro-inflammatory T cell inhibition on exogenous MSCs.

All these results suggest that intravenous substance P can promote bone repair. Similar to our findings, another group has recently promoted bone repair through local application of substance P9. However, in our model, we highlighted the combination of systemic infusion of substance P with local-transplanted MSCs in bone repair, which not only took advantage of endogenous MSCs, but also promoted the survival of local-transplanted MSCs. Moreover, we observed that the Runx2 expression within the defect sites, which was associated with osteogenesis of mesenchymal stem cells, was enhanced after intravenous substance P injection, suggesting that systemic infusion of substance P together with its mobilized MSCs could promote osteogenesis of local MSCs in the bone defect animals. All these above results indicate that i.v. substance P can effectively promote bone repair in the calvarial defect mice.

Collectively, our study highlights the effects of substance P in bone repair through mobilizing endogenous MSCs and also indicates the possible roles of intravenous substance P in regulating inflammatory conditions in bone defects. In addition, the combination of intravenous substance P and local-transplanted MSCs treatment can effectively promote the osteogenesis of MSCs and boost calvarial bone repair.

Methods

Animal experiments. For the first part of animal experiments, twelve C57BL/6 wide-type mice (10-week-old) were randomly divided into four groups: uninjured, calvarial injured, uninjured + i.v. substance P and calvarial injured + i.v. substance P groups. We established the calvarial critical-sized defect model with a diameter of 5 mm. In uninjured + i.v. substance P and calvarial injured + i.v. substance P groups, each mouse was given a systemic injection of substance P (5 nmol/kg, dissolved in phosphate-buffered saline) through the tail vein. 3 days after surgery, we collected 1 ml peripheral blood and counted CD45+CD11b+CD29+ cells using flow cytometry.

For the second part of animal experiments, thirty C57BL/6 wide-type mice (10-week-old) were randomly divided into five groups: control, blank scaffold, i.v. GFP+MSCs, GFP+MSCs-scaffold and GFP+MSCs + i.v. substance P groups. We established the calvarial critical-sized defect model with a diameter of 5 mm. In blank scaffold group, we put the 5 × 5 mm² gelatin sponge within calvarial defect area. In i.v. GFP+MSCs group, we gave each mouse a systemic injection of 5 × 10⁶ GFP+MSCs (dissolved in 200 µl phosphate-buffered saline) through its tail vein. In GFP+MSCs-scaffold group, the 5 × 5 mm² gelatin sponge seeded with GFP+MSCs was set in calvarial defect area of each mouse. In GFP+MSCs + i.v. substance P groups, we put one GFP+MSCs-seeded scaffold in calvarial defect area and gave each mouse a systemic injection of substance P (5 nmol/kg, dissolved in phosphate-buffered saline) through the tail vein.

Flow cytometry. 3 days after surgery, 1 ml peripheral blood was harvested from calvarial injured mice (uninjured, calvarial injured, uninjured + i.v. substance P and calvarial injured + i.v. substance P groups). Each sample from an individual mouse was separately prepared and incubated with the antibodies CD29 (BioLegend, San Diego, CA), CD11b (BioLegend, San Diego, CA), CD45 (BioLegend, San Diego, CA), CD45 (BioLegend, San Diego, CA) for 30 minutes at 4 °C. FlowJo was used for flow cytometric analyses.

Cell counting and CCK8. Substance P-mobilized CD29+ cells were isolated by MACS sorting (Miltenyi) from the peripheral blood at 3 days after surgery (uninjured, calvarial injured, uninjured + i.v. substance P and calvarial injured + i.v. substance P groups). All the single cells were seeded at 1 × 10⁴ into 100 mm culture dishes (Corning, NY, USA) and incubated in α-MEM medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin (all from Gibco, Grand Island, NY, USA) at 37 °C and 5% CO₂. Medium was changed after 3 days. Then we treated these cells with different doses of substance P (0 mol/l, 1 × 10⁻⁶ mol/l, 1 × 10⁻⁸ mol/l and 1 × 10⁻⁴ mol/l). After 48 hours of treatment, cell counting was performed.

CCK8 was also carried out. We seeded 4 × 10⁴ CD29+ cells in each well of 96-well plate in 100 µl culture medium and pre-inoculated the plate for 24 hours at 37 °C and 5% CO₂. Then the cells were treated with 1 × 10⁻¹⁰ mol/l, 1 × 10⁻⁸ mol/l and 1 × 10⁻⁴ mol/l of substance P in three experiment groups respectively. After 48 hours of treatment, 10 µl of CCK8 solution (Dojindo, Tabaru, Japan) was added to each well of the plate. After 2-hour incubation at 37 °C and 5% CO₂, the optical density (OD) value of each well was measured at 450 nm using a microplate reader (Bio-Rad, Hercules, CA, USA).
was quantitatively analyzed by the ratio of the gray value between the target protein and β-actin in the same sample. The membranes were washed and incubated for 1 h in the peroxidase-conjugated secondary antibody (Cruz Biotechnology, Dallas, TX), GFP (Cell Signaling, Danvers, MA) and Runx2 (Abcam, Cambridge, UK). After γ-irradiation with primary antibodies for IFN-γ (Abcam, Cambridge, UK), TNF-α (Abcam, Cambridge, UK) and TSG-6 (Santa Cruz Biotechnology, Dallas, TX) was assayed by ELISA for IFN-γ (Abcam, Cambridge, UK), TNF-α (Abcam, Cambridge, UK), and TSG-6 (Santa Cruz Biotechnology, Dallas, TX). The supernatant were collected for the whole protein extraction. The membranes were blotted for 4–6 hours, 500 μl medium was added to each well. These prepared scaffolds were used in the second part of animal experiments.

**Scaffold processing.** Under sterile conditions, the gelatin sponge was cut into a size of about 5 × 5 mm² and incubated in 48-well plates with culture medium for 12 hours; after that, the medium was discarded; then P1 MSCs were seeded in the 48-well plates with a number of 1 × 10⁶ within 100 μl medium per well. After incubation for 4–6 hours, 500 μl medium was added to each well. These prepared scaffolds were used in the second part of animal experiments.

**ELISA.** 2 weeks after the surgery, 1 ml peripheral blood was harvested from each mouse in five groups (control, blank scaffold, i.v.GFP+ MSCs, GFP+ MSCs-scaffold and GFP+ MSCs + i.v.substance P groups) and set stable for 30 min. After centrifugation at 3000 r.p.m. at 4 °C for 10 minutes, the supernatant was collected and assayed by ELISA for IFN-γ (Abcam, Cambridge, UK), TNF-α (Abcam, Cambridge, UK) and TSG-6 (Santa Cruz Biotechnology, Dallas, TX).

**Western blot.** 2 weeks post surgery half of the mice from each group (control, blank scaffold, i.v.GFP+ MSCs, GFP+ MSCs-scaffold and GFP+ MSCs + i.v.substance P groups) were sacrificed. Half of the tissue within the calvarial injury site from each sacrificed mouse was collected and washed with PBS, and then grinded in liquid nitrogen. Lysed in RIPA buffer (KeyGEN Biotech, China) and then put on ice for 30 min. Centrifuged for 20 min at 4 °C, 12000 g. Then, the supernatant was collected for the whole protein extraction. The membranes were blotted with primary antibodies for IFN-γ (Abcam, Cambridge, UK), TNF-α (Abcam, Cambridge, UK), TSG-6 (Santa Cruz Biotechnology, Dallas, TX), GFP (Cell Signaling, Danvers, MA) and Runx2 (Abcam, Cambridge, UK). After primary antibody incubation, the membranes were washed and incubated for 1 h in the peroxidase-conjugated anti-mouse or rabbit secondary antibody (ZSGB-BIO, China, 1:5000). The relative expression of the tested protein was quantitatively analyzed by the ratio of the gray value between the target protein and β-actin in the same sample.

**Quantitative real-time PCR.** For RNA extraction, the other half of the tissue within the calvarial injury site from each sacrificed mouse was collected, minced into small pieces, lysed in RNA isolation reagent (Trizol; Gibco, US), and homogenized using a motor-driven homogenizer. The total RNA was extracted using RNAiso Plus (TaKaRa, Japan). First-strand cDNA was synthesized from 1 μg total RNA using a Reverse Transcriptase PCR Kit (Thermo, Germany). Real-time amplification was performed using Applied Biosystems Prism 7900HT Sequence Detection System (Thermo, Germany). The primers are listed in Table 1.

**Real-time in vivo GFP fluorescence imaging.** 12 weeks post surgery, the expression of GFP+ signal from each group (control, blank scaffold, i.v.GFP+ MSCs, GFP+ MSCs-scaffold and GFP+ MSCs + i.v.substance P groups) was detected by Bio-Real in vivo imaging system (Bio-Real, QuickView3000, Austria). The wavelength of excitation light was 474 nm, and the wavelength of emitted light was 525 nm.

**Micro-CT scanning with image reconstruction.** 12 weeks after surgery, the remaining mice from each group (control, blank scaffold, i.v.GFP+ MSCs, GFP+ MSCs-scaffold and GFP+ MSCs + i.v.substance P groups) were sacrificed and the calvarial bones were dissected and fixed in 4% paraformaldehyde. Micro-CT scan and image reconstruction were performed by VGStudio Max2.1 software. The total volume, relative bone volume (BV/TV), bone mineral density (BMD), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) were analyzed.

| Gene | Primer sequence (5’→3’) |
|------|-------------------------|
| IFN-γ | (F) GAGTATTGCCAAGTTGAGGT<br> (R) CAGGACTCTTTTCTCCGCT |
| TNF-α | (F) CAGGCTGACAAAACCCAA<br> (R) GTCGTTGTTGCTTGAACCCAT |
| TSG-6 | (F) TGACCTTGAACATGATCAG<br> (R) CTTCAAGGTCATGACCTCCT |
| Runx2 | (F) CAAGAGTTACACCCGTAGCAT<br> (R) GTCAACAGCTCTGTCTG |
| GFP | (F) CCACATGAAAGCAGGACT<br> (R) GATGCCGTTACACGAGGTG |

Table 1. Primer sequence for RT-PCR.
Hematoxylin-eosin staining. After fixation in 4% paraformaldehyde and Micro-CT scan, the calvarial bones were then decalcified with 5% ethylenediaminetetraacetic acid (EDTA, pH 7.4), followed by paraffin embedding. Coronal sections of 5 μm thickness were obtained. Hematoxylin-eosin stainings were performed for microscopic observation of the sections.

Statistics. SPSS 20.0 was used to do the statistical analyses. Significance was assessed using an independent two-tailed Student's t test or with analysis of variance. P < 0.05 was considered significant.

Ethical Approval. Ethical approval to report this case series was obtained from Ethics Committee of West China School of Stomatology (approval number: WCCSIRB-D-2014-020).

Statement of human and animal rights. All procedures in this study were conducted in accordance with the Ethics Committee of West China School of Stomatology's approved protocols (WCCSIRB-D-2014-020). This article does not contain any studies with human subjects.

Data Availability
All data generated or analyzed during this study are included in this published article.

References
1. Mele, L. et al. Changing Paradigms in Cranio-Facial Regeneration: Current and New Strategies for the Activation of Endogenous Stem Cells. Front Physiol 7, 62, https://doi.org/10.3389/fphys.2016.00062 (2016).
2. Mao, J. J. et al. Facial reconstruction by biosurgery: cell transplantation versus cell homing. Tissue Eng Part B Rev 16, 257–262, https://doi.org/10.1089/ten.TEB.2009.0496 (2010).
3. Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K. & Giannoudis, P. V. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury 42(Suppl 2), S3–S15, https://doi.org/10.1016/j.injury.2011.06.015 (2011).
4. Lee, S. W. et al. Stem cell-mediated accelerated bone healing observed with in vivo molecular and small animal imaging technologies in a model of skeletal injury. J Orthop Res 27, 295–302, https://doi.org/10.1002/jor.20736 (2009).
5. Caplan, A. I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213, 341–347, https://doi.org/10.1002/jcp.21200 (2007).
6. Horwitz, E. M. et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5, 309–313, https://doi.org/10.1038/nm.6529 (1999).
7. Awa, N., Rupert, K., Bryant, E. & Torok-Storb, B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol 30, 937–942 (2002).
8. Höftstetter, C. P. et al. Alloxdynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci 8, 346–353, https://doi.org/10.1038/nn1405 (2005).
9. Liu, Y. et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 17, 1594–1601, https://doi.org/10.1038/nm.2542 (2011).
10. Hamou, C. et al. Mesenchymal stem cells can participate in ischemic neovascularization. Plast Reconstr Surg 123, 455–555, https://doi.org/10.1097/PRS.0b013e318191be4a (2009).
11. Kumagai, K., Vasani, A., Drabza, J. A., Butler, B. S. & Muschler, G. F. Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. J Orthop Res 26, 165–175, https://doi.org/10.1002/jor.20477 (2008).
12. Hong, H. S. et al. A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med 15, 425–435, https://doi.org/10.1038/nm.1909 (2009).
13. Nicoletti, M. et al. Impact of neuropetide substance P an inflammatory compound on arachidonic acid compound generation. Int J Immunopathol Pharmacol 28, 849–857, https://doi.org/10.1177/03946320202102000403 (2012).
14. Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5, 54–63, https://doi.org/10.1016/j.stem.2009.05.003 (2009).
15. Choi, H., Lee, R. H., Bazhanov, N., Oh, J. Y. & Prockop, D. J. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 118, 330–338, https://doi.org/10.1182/blood-2010-12-327353 (2011).
16. Oh, J. Y. et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther 20, 2143–2152, https://doi.org/10.1038/mt.2012.165 (2012).
17. Yang, Y., Yan, M., Zhang, H. & Wang, X. Substance P participates in immune-mediated hepatic injury induced by concanavalin A in mice and stimulates cytokine synthesis in Kupffer cells. Exp Ther Med 6, 459–464, https://doi.org/10.3892/etm.2013.1152 (2013).
18. Yeo, C. J., Jaffe, B. M. & Zimmer, M. J. The effects of intravenous substance P infusion on hemodynamics and regional blood flow in conscious dogs. Surgery 95, 175–182 (1984).
19. Zachar, L., Bacenkova, D. & Rosocha, J. Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment. J Inflamm Res 9, 231–240, https://doi.org/10.2147/JIR.S121994 (2016).
20. Kim, S. H., Kim, J. E., Kim, S. H. & Jung, Y. Substance P/dexamethasone-encapsulated PLGA scaffold fabricated using supercritical fluid process for calvarial bone regeneration. J Tissue Eng Regen Med. https://doi.org/10.1002/term.2260 (2017).

Acknowledgements
We thank members of the Wang laboratory for valuable discussions. This work was supported by National Natural Science Foundation of China (No. 81771114 and No. 81470776).

Author Contributions
J.W. and Y.Z. designed the project. Y.Z., S.A., J.H., F.T. and X.F. conducted experiments and analyzed data. Y.Z. and S.A. performed animal surgeries and cell culture. Y.Z. and S.A. conducted flow cytometry, ELISA, fluorescence imaging and MicroCT scanning. J.H. performed western blot and quantitative real-time PCR. X.F. conducted tissue staining. J.H. and F.T. provided technical expertise and assisted in data interpretation. J.W., Y.Z. and S.A. wrote the manuscript. All authors critically read and contributed to the manuscript.

Additional Information
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018